#AbbVie #BMS #BristolMyersSquibb #UKdrugpricing #pharmagroup #newmedicines #UK #USA #ovariancancertherapy #Elahere #NHSpatients #reimbursementauthority #NICE #schizophrenia #Cobenfy #pharmacompanies #Trump #medicineprices #MHRA #VPAG #rebates #NHS #MSD #EliLilly #AstraZeneca
zurl.co/d8CQZ
zurl.co/d8CQZ
AbbVie joins BMS in taking a hard line on UK drug pricing
AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.
pharmaphorum.com
October 3, 2025 at 11:57 AM